JP2019531286A - Ｃｈｓ−１３１による多発性硬化症の治療 - Google Patents

Ｃｈｓ−１３１による多発性硬化症の治療 Download PDF

Info

Publication number
JP2019531286A
JP2019531286A JP2019513922A JP2019513922A JP2019531286A JP 2019531286 A JP2019531286 A JP 2019531286A JP 2019513922 A JP2019513922 A JP 2019513922A JP 2019513922 A JP2019513922 A JP 2019513922A JP 2019531286 A JP2019531286 A JP 2019531286A
Authority
JP
Japan
Prior art keywords
effective amount
therapeutically effective
compound
multiple sclerosis
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019513922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531286A5 (enExample
Inventor
バルバラ フィンク
バルバラ フィンク
ロバート ジバディノフ
ロバート ジバディノフ
ホン タン
ホン タン
Original Assignee
インテクリン セラピューティクス インコーポレイテッド
インテクリン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテクリン セラピューティクス インコーポレイテッド, インテクリン セラピューティクス インコーポレイテッド filed Critical インテクリン セラピューティクス インコーポレイテッド
Publication of JP2019531286A publication Critical patent/JP2019531286A/ja
Publication of JP2019531286A5 publication Critical patent/JP2019531286A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019513922A 2016-09-13 2017-09-13 Ｃｈｓ−１３１による多発性硬化症の治療 Pending JP2019531286A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662394046P 2016-09-13 2016-09-13
US62/394,046 2016-09-13
US201662436356P 2016-12-19 2016-12-19
US62/436,356 2016-12-19
US201762460868P 2017-02-19 2017-02-19
US62/460,868 2017-02-19
US201762491071P 2017-04-27 2017-04-27
US62/491,071 2017-04-27
PCT/US2017/051414 WO2018053040A1 (en) 2016-09-13 2017-09-13 Treatment of multiple sclerosis with chs-131

Publications (2)

Publication Number Publication Date
JP2019531286A true JP2019531286A (ja) 2019-10-31
JP2019531286A5 JP2019531286A5 (enExample) 2020-10-22

Family

ID=61619253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513922A Pending JP2019531286A (ja) 2016-09-13 2017-09-13 Ｃｈｓ−１３１による多発性硬化症の治療

Country Status (12)

Country Link
US (1) US20190224186A1 (enExample)
EP (1) EP3512512A4 (enExample)
JP (1) JP2019531286A (enExample)
KR (1) KR20190064583A (enExample)
CN (1) CN110461318A (enExample)
AU (1) AU2017326261A1 (enExample)
BR (1) BR112019004791A2 (enExample)
CA (1) CA3036694A1 (enExample)
IL (1) IL265259A (enExample)
MX (1) MX2019002901A (enExample)
SG (1) SG10202102198RA (enExample)
WO (1) WO2018053040A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
EA201992364A1 (ru) * 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507537A (ja) * 2003-10-03 2007-03-29 アムジェン インコーポレーテッド 強力な抗糖尿病薬化合物の塩および多形体
JP2016506956A (ja) * 2013-01-30 2016-03-07 インテクリン・セラピユーテイクス・インコーポレイテツド 多発性硬化症を治療するためのＰＰＡＲγアゴニスト

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201590726A1 (ru) * 2012-10-12 2015-10-30 Тева Фармасьютикал Индастриз Лтд. Лахинимод для уменьшения таламического поражения при рассеянном склерозе

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507537A (ja) * 2003-10-03 2007-03-29 アムジェン インコーポレーテッド 強力な抗糖尿病薬化合物の塩および多形体
JP2016506956A (ja) * 2013-01-30 2016-03-07 インテクリン・セラピユーテイクス・インコーポレイテツド 多発性硬化症を治療するためのＰＰＡＲγアゴニスト

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRAIN, vol. 122, JPN6021025537, 1999, pages 871 - 882, ISSN: 0004870728 *
CLINICALTRIALS.GOV ARCHIVE NCT02638038 ON 2015_12_20, ２０１５年１２月２０日，RETRIEVED FROM THE INT, JPN6021025539, 20 December 2015 (2015-12-20), ISSN: 0004870727 *
甲南女子大学研究紀要第２号 看護学・リハビリテーション学編, JPN6022014978, 2009, pages 107 - 112, ISSN: 0004870729 *

Also Published As

Publication number Publication date
CN110461318A (zh) 2019-11-15
IL265259A (en) 2019-05-30
EP3512512A1 (en) 2019-07-24
WO2018053040A1 (en) 2018-03-22
BR112019004791A2 (pt) 2019-06-04
CA3036694A1 (en) 2018-03-22
EP3512512A4 (en) 2020-06-03
AU2017326261A1 (en) 2019-04-04
SG10202102198RA (en) 2021-04-29
MX2019002901A (es) 2019-09-26
US20190224186A1 (en) 2019-07-25
KR20190064583A (ko) 2019-06-10

Similar Documents

Publication Publication Date Title
EP3206682B1 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
JP2017200927A (ja) ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療
KR20150013658A (ko) 다발성 경화증을 치료하기 위한 고용량의 라퀴니모드의 용도
JP2017061482A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
JP2019531286A (ja) Ｃｈｓ−１３１による多発性硬化症の治療
RU2563821C2 (ru) Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы
JPWO2000009127A1 (ja) 多発性硬化症治療薬
US12318380B2 (en) Treatment of demyelinating diseases
JP2016506956A (ja) 多発性硬化症を治療するためのＰＰＡＲγアゴニスト
CN119421710A (zh) 偏头痛的预防治疗
RU2738886C2 (ru) Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
US12290522B2 (en) Method of treating amyotrophic lateral sclerosis
EP4437000A1 (en) Anti-trem2 antibody and uses thereof
US20240415846A1 (en) Method of treating amyotrophic lateral sclerosis and dosing regimen for same
JP2012102069A (ja) 早漏治療剤
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
US20240299410A1 (en) Methods of treating familial amyotrophic lateral sclerosis by oral administration of fasudil
WO2025124760A1 (en) Treatment of subpopulation of patients with rheumatoid arthritis
KR20250034083A (ko) 신경퇴행성 질환을 치료 또는 예방하기 위한 조성물 및 방법
AU2024273942A1 (en) Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2025248089A1 (en) Haloquinolines for treating immune-mediated inflammatory diseases
JP6551671B2 (ja) アルツハイマー治療薬
HK1224555A1 (en) Use of high dose laquinimod for treating multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200911

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220819

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220826

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220829

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220916

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220921